TNFRSF17 and plasma cell myeloma: The second most advanced CAR-T cell construct (LCAR-B38M) in development consists of a dual epitope specific Fv targeting BCMA antigen and is being developed by Legend Biotech/Johnson & Johnson to treat relapsed refractory multiple myeloma [25].